Abstract D 2/3 receptor agonists are effective treatments for Parkinson's disease (PD), but can precipitate impulse control disorders (ICDs) including gambling disorder (GD). The neurobiological mechanisms underlying this devastating side-effect of dopamine agonist replacement therapy (DRT), and any dependence on the dopamine depletion caused by PD, are unclear. It is also unclear whether previous biases towards risk or uncertainty are a risk factor for developing these ICDs. We investigated whether chronic D 2/3 agonist administration (5 mg/kg/day ropinirole for 28 days) altered performance of a rat model of gambling-like behaviour, the rodent betting task (rBT), and examined if baseline behaviour predicted this behavioural change. The rBT captures individual differences in subjective preference for uncertain outcomes: animals choose between guaranteed or probabilistic reinforcement of equal expected value. Chronic ropinirole dramatically increased selection of the uncertain option in two-thirds of animals, regardless of baseline preferences. The effect on choice in the rBT was replicated in a dorsolateral striatal 6-hydroxydopamine (6-OHDA) rat model of early PD. These studies are the first to look at individual differences in response to chronic, rather than pulsatile, dosing of DRT in a rodent model of gambling behaviour. These findings suggest that DRT-induced PG may stem from increases in subjective valuation of uncertainty. Such symptoms likely arise because of changes in dopaminergic striatal signalling caused by DRT rather than from an interaction between pre-morbid behaviours or PD itself.
Introduction
Although highly effective at ameliorating motor and neuropsychiatric symptoms of Parkinson's disease (PD), dopamine D 2/3 receptor agonist replacement treatments (DRT) can engender impulse control disorders (ICDs) such as gambling disorder (GD) in a subgroup of patients. Such DRT-ICDs result in significant psychosocial distress and serious impairments in quality of life that can even surpass the disability caused by PD Weintraub et al., , 2010 Voon et al., 2011b) . Similarly, DRT can precipitate ICDs in other patient groups for which they are prescribed, including restless leg syndrome (Voon et al., 2011c) .
While effective in the treatment of movement disorders, many neurologists may therefore hesitate to use DRTs for fear of initiating such a catastrophic cascade of side-effects to which a minority of patients appear vulnerable. Ideally, those at risk of DRT-ICDs would be reliably identified before treatment was initiated. Some studies suggest that both a previous history of ICDs in the patient or their families may confer vulnerability (Voon et al., 2007) , although this does not account for every case (Voon et al., 2011d) . It is therefore unclear if the change in risky choice in PD patients may be attributed to a combination of pre-morbid factors and DRT, or to individual differences in the physiological reaction to DRT that may depend on, or be independent from, PD.
Animal models that capture changes in impulse control or risky decision-making, and that are sensitive to chronic DRT administration, could make a significant contribution in this regard; the tighter degree of experimental control possible makes it easier to determine whether pre-morbid behavioural traits contribute to a maladaptive drug response. Such models could also help elucidate the biological mechanism underlying DRT-induced changes in decision-making, and contribute to the search for adjunctive drug treatments that would offset the psychiatric complications of DRT while preserving the control of motor symptoms.
Similar to individuals with GD, PD patients show deficits in a variety of decision-making tasks. Individuals with problem gambling make higher rates of risky choices even when the probability of reward decreases on a probability discounting task (Madden et al., 2009) , and PD patients on DRTs (including dopamine agonists and levodopa) show increased risky decisions on probabilistic tasks such as the Game of Dice (Labudda et al., 2010; Brandt et al., 2015) . Recent work suggests that repeated administration of pramipexole, a dopamine D 2/3 agonist used in the treatment of PD, increases choice of the risky option on a probability discounting task in both healthy rats and in a rat model of PD . These landmark findings therefore suggest that DRT alone is primarily responsible for the behavioural changes observed.
This study was designed to further test this important hypothesis, and also to determine whether individual differences in basal preference for uncertain outcomes influenced response to the drug. We therefore assessed whether chronic administration of the dopamine D 2/3 agonist ropinirole altered performance of the rodent Betting task (rBT; Cocker et al., 2012a) . This task, which simply measures preference for certain vs. uncertain rewarding outcomes of equal utility, reliably allows for the objective observation of marked individual differences in choice; as the amount of reward at stake increases, some rats shift their preference towards the guaranteed outcome, whereas the choice of others remains indifferent to the change in wager size (Cocker et al., 2012b; Tremblay et al., 2014) . Ropinirole was delivered via osmotic mini-pump, in order to assess whether behavioural change would still be evident using a 'slowrelease' formulation, as opposed to pulsatile drug delivery . We subsequently independently replicated the behavioural effects of chronic ropinirole in rats with selective lesions of the dopaminergic fibres innervating the dorsolateral striatum, reminiscent of early-stage PD (Baunez et al. 1995 , Baunez et al., 2007 .
Materials and methods
Further details of all protocols can be found in Supporting Information (Appendix S1).
Subjects
Male Long Evans rats (n = 68; initial weight: 250-275 g; Charles River, St. Constant, Canada) were pair-housed with free access to water under a reverse light cycle in a climate-controlled colony. Rats were food restricted to 85% of their free-feeding weight and maintained on 14 g of standard rat chow per day plus any sugar pellets earned on task (~5 g per day) throughout each experiment. Behavioural testing took place in 28 standard five-hole operant chambers (Med Associates, Roanopke, VA). All experimental practices were in accordance with the Canadian Council on Animal Care, and approved by the Animal Care Committee of the University of British Columbia.
Experiment 1: effect of chronic ropinirole in healthy rats
The rBT. Subjects (n = 24) were trained to perform the rBT as described previously (Cocker et al., 2012a; Tremblay et al., 2014) . Briefly, subjects chose between a safe lever that delivered a guaranteed amount of sugar reward, or an uncertain lever which delivered either double the safe reward or nothing with 50 : 50 odds (Fig. 1A for task schematic). The bet size in play was equivalent to the number of response holes illuminated at the start of each trial. Training continued until a stable pattern of choice was established, defined as non-significant main effects of, or interactions with, the session factor in a repeated measures ANOVA of any behavioural parameters over five sessions (total sessions to behavioural stability: experiment 1: 64; experiment 2: 46). Animals in experiment 2 were then trained intermittently for a further 5 months to approximate the mid-life age at which early-onset PD occurs (Fig. 1B for experimental timeline for each experiment).
Osmotic pump implantation. Animals (n = 24) were divided into two groups of rats, matched for their baseline performance. Rats were anesthetized and subcutaneously implanted with an osmotic pump delivering either 5 mg/kg/day of ropinirole hydrochloride (n = 12) or 0.09% saline solution (n = 12) for 28 days. The pump was then removed and behavioural training continued for a further 4 weeks. The osmotic pump allows for 28 days of chronic drug delivery, and its use has been validated in multiple experiments Fig. 1 . (A) Schematic of the rodent betting task (rBT). Each trial began by making a nose-poke response at the illuminated food tray. The tray light was then extinguished, and 1-3 response holes were illuminated, signalling the size of the bet/wager (1-3 sugar pellets). A nose-poke response at an illuminated aperture turned off the light inside it. Once all of the aperture lights had been extinguished in this manner, two levers were presented to the rat. Selection of the uncertain lever resulted in a 50 : 50 chance of receiving either double the wager or nothing, whereas selection of the safe lever always led to delivery of the wager. The trial was scored as a choice omission if the rat failed to choose one of the levers within 10 s. Likewise, if the rat failed to respond at each illuminated response hole within 10 s, the trial was scored as a hole omission. Adapted with permission from Cocker et al. (2012b) . ( (e.g. Kapur et al., 2003; Kemmerer et al., 2003; Kippin et al., 2005; Vernon et al., 2012) . Although the half-life of ropinirole is 5-6 h in humans, it is only 0.5 h in rats (Ramji et al., 1999) . Acute doses in the range of 1-5 mg/kg in rats did not induce turning behaviours in a 6-OHDA model of PD nor affected spatial memory and motor functions (Fukuzaki et al., 2000; Mavrikaki et al., 2014) . However, if administered chronically, these doses surpass the therapeutic range used in humans (Nashatizadeh et al., 2009) . Therefore, for this experiment, we chose a dose that showed neuroprotective effects and reduction in anxiety, but had no effect on locomotion or cognition, although it improved motor deficits in rats overexpressing D 2/3 receptors (Iida et al., 1999; Rogers et al., 2000; Millan et al., 2004; Matsukawa et al., 2007) . The dose used here is also similar to the single daily dose of the prolonged released formulation of ropinirole used in human patients (Nashatizadeh et al., 2009) .
Experiment 2: effect of chronic ropinirole in the 6-OHDA model of early PD Bilateral dorsolateral striatal 6-OHDA lesion surgery. The bilateral dorsolateral striatal 6-OHDA lesion rat model is commonly used as a model for early PD and features loss of dopamine terminal similar to those observed in PD (Przedborski et al., 1995; Deumens et al., 2002; Baunez et al., 2007; Blesa et al., 2012) . In PD patients, dopamine neurons of the substantia nigra pars compacta begin to die. As bilateral lesion to this area in rodents leads to severe motivational deficits which could interfere with our task performance (see Magnard et al., 2016 for review), the bilateral dorsolateral striatal 6-OHDA lesion model was used instead as a proxy for early-stage PD. Although lesioned animals may show persistent forelimb motor impairment following striatal lesions, this model allows performance of complex behavioural tasks without development of side biases (Przedborski et al., 1995; Deumens et al., 2002; Baunez et al., 2007; Blesa et al., 2012; . Here, animals (n = 43) were first trained on the rBT as above and divided into two groups matched for baseline performance. Rats then received either bilateral dorsolateral striatal lesions (n = 22) containing 12 lg/3 lL of 6-OHDA, or sham-lesion (n = 21) using standard stereotaxic techniques. Coordinates were: AP: +0.2 mm; ML: AE3.5 mm; DV: À4.5, taken from bregma, midline and skull respectively; incisor bar at À3.3. Following behavioural stability, animals were again divided into two matched groups, and implanted with a pump delivering either ropinirole (n = 22; 11 lesioned rats, 11 sham rats) or saline (n = 21; 11 lesioned rats, 10 sham rats) for 28 days as per experiment 1.
Ex vivo analysis. All animals were killed by live decapitation. In experiment 2, tyrosine hydroxylase immunohistochemistry was performed to determine the extent of 6-OHDA lesions.
Data analysis
Analyses were conducted using SPSS (version 22, SPSS/IBM, Chicago, USA). Behaviour was assessed at baseline prior to all surgical procedures, following 6-OHDA lesion, and throughout the 28 days of ropinirole delivery. In experiment 1, behaviour was also assessed for 4 weeks following removal of the osmotic pump. Data were analysed in weekly bins of five daily sessions. Data were subjected to a within-subjects repeated measure analysis of variance (ANOVA) with session (five levels, sessions 1-5) as a within-subjects factor and drug (two levels, ropinirole vs. saline) as a between-subjects factor. The Greenhouse-Geisser correction was applied whenever the assumption of sphericity was violated. In the rBT, the key dependent variable was the percent choice of the uncertain lever, analysed as a within-subjects factor across bet size (three levels, 1-3 sugar pellets). As per our previous report (Cocker et al., 2012a) , individual rats were classified as wager-sensitive or wager-insensitive based on their choice of the uncertain option as a function of bet size (Supporting Information), and this between-subjects factor was also included in all analyses (wager-sensitivity, two levels). In the model of early PD, surgery group (two levels, sham vs. lesion) was also added as a between-subjects factor. In order to determine if this response to ropinirole was present in all rats, or just within a subgroup of responders, individual ANOVAs were performed on data from each rat, in which the final five sessions of ropinirole treatment were compared to five baseline sessions with a single within-subjects factor (time point, two levels). A Chi-Squared analysis on the number of responders/non-responders and wager-sensitive/non-sensitive rats was then performed.
Results
Additional analyses can be found in Supporting Information (Appendix S1).
Experiment 1: effect of chronic ropinirole in healthy rats
The rBT
Wager-insensitive rats (n = 14) sampled fairly equally from both the safe and uncertain levers, regardless of the bet size in play (bet size: F 2,26 = 0.02, P = 0.982, NS), whereas wager-sensitive animals (n = 10) drastically decreased their preference for the uncertain reward as the bet size increased (bet size: F 2,18 = 53.74, P < 0.001).
Chronic ropinirole increased choice of the uncertain lever across all bet sizes, regardless of animals' baseline preference for the safe or uncertain option ( Fig. 2A-B ; week 4-treatment group: F 1,20 = 10.89, P = 0.004; treatment group 9 bet size, Fig. 2C-F ; treatment group 9 wager-sensitivity: all Fs < 2.46, all Ps > 0.098, NS). This change was evident from week 2 onwards (see Supporting Information for statistics, Appendix S1; Table S2 ). Four weeks after the osmotic pump was removed, choice behaviour in the ropiniroleand saline-treated groups was no longer significantly different (withdrawal week 4, treatment group: F 1,20 = 0.44, P = 0.515, NS; treatment group 9 wager-sensitivity: F 1,20 = 1.08, P = 0.310, NS). Human patients differ in sensitivity to dopamine agonist therapy. Contrary to our expectations, the degree of wager sensitivity did not affect the response to ropinirole, as would be expected if predisposition to gambling behaviour was responsible for the development of ICDs. We performed additional analyses to determine whether a subgroup of rats drove the effect of ropinirole, or if instead this increase in uncertain choices was universal. These analyses identified 8 out of 12 rats as 'responders'-those who increased their choice of the uncertain lever in response to ropinirole split equally between the wager-sensitive (n = 4) and wager-insensitive (n = 4) subgroups (Fig. 2G-H drug treatment week 4 vs. baseline, responders vs. non-responders: time point x group: F 1,8 = 13.35, P = 0.006; responders only, time point: F 1,6 = 52.10, P < 0.001; non-responders only; time point: F 1,2 = 2.59, P = 0.249, NS; analysis by wager-sensitivity; all Fs < 4.10, all Ps > 0.089, NS; number of responders/non-responders and wager-sensitive/wager-insensitive: v 2 (1) = 0.686, P = 0.408, NS).
Experiment 2: effect of chronic ropinirole in a 6-OHDA model of Parkinson's Disease
As is typical for this model (Baunez et al., 2007; Riddle et al., 2012; , 6-OHDA lesion resulted in visible loss of tyrosine hydroxylase immunostaining within the dorsolateral region of the striatum (Fig. 3A) . However, lesion to this area did not affect choice behaviour (surgery group, surgery group 9 wagersensitivity, surgery 9 bet size: all Fs < 1.58, all Ps > 0.216, NS). Chronic ropinirole increased choice of the uncertain lever at the largest bet size regardless of whether the animal underwent lesion or sham surgery, or the animals' wager-sensitivity ( Fig. 3B-C ; week 4-treatment group: F 1,35 = 3.22, P = 0.081, NS; treatment group 9 bet size: F 2,49.47 = 5.59, P = 0.013; treatment group 9 surgery group: F 1,35 = 0.276, P = 0.603, NS; treatment group 9 wager-sensitivity: F 1,35 = 0.022, P = 0.883, NS). This change only appeared during the last week of ropinirole administration (additional statistics in Supporting Information; Table S4 ). Similar to experiment 1, we explored whether a subgroup of animals drove the effect of the drug. Analyses identified a similar proportion of rats (16 out of 22) as 'responders', split equally between the wager-sensitive (n = 8) and wager-insensitive (n = 8) subgroups ( Fig. 3D-E ; drug treatment week 4 vs. baseline, responders vs. nonresponders: time point 9 group: F 1,18 = 44.17, P < 0.001; responders only; time point: F 1,12 = 33.99, P < 0.001; non-responders only; time point: F 1,2 = 15.01, P = 0.061, NS; analysis by surgery group and by wager sensitivity, all Fs < 0.64, all Ps > 0.441, NS; number of responders/non-responders and wager-sensitive/wagerinsensitive: v 2 (1) = 0.489, P = 0.484, NS).
Discussion
Here, we show that chronic ropinirole treatment increased preference for the uncertain option on the rBT in roughly two-thirds of subjects. The ability of ropinirole to bias choice towards the probabilistic delivery of reward on this task was not altered by 6-OHDA lesions of the dorsolateral striatum, an animal model of early PD, either with respect to the magnitude of the change in choice, or the proportion of animals affected. Even though we could detect substantial variation in subjects' baseline preference for the probabilistic option in the rBT, these individual differences did not predict the response to ropinirole treatment. Collectively, these data support the hypothesis that the altered judgment exhibited by patients with PD or restless leg syndrome following chronic DRT administration can be largely attributed to the direct actions of the drugs themselves (Weintraub, 2008; , rather than resulting from an interaction between the medication and basal risk preference, or any change in dopamine function caused by the diseases for which they were originally prescribed. Whenever attempts are made to extrapolate from rat to human behaviour, we must consider the degree to which the rodent tasks accurately capture the cognitive trait in question. The rBT was developed as one of a series of tasks aiming to capture non-normative decision-making biases evident in human decision-making under uncertainty (see Cocker & Winstanley, 2015 for discussion). Psychobiological accounts of GD posit that the strength of these cognitive distortions can contribute to the aetiology and severity of GD (Clark, 2010) . Furthermore, the rBT is very similar to the 'gain' condition of a gambling-like task used recently to compare choice patterns of PD patients with and without ICDs, in which PD-ICD patients exhibited significantly greater preference for uncertain outcomes (Voon et al., 2011a) . As in the standard trials in Voon's 2011 task, there was no real risk in the rBT as the expected value of both the uncertain and safe option was the same. This differs from other similar tasks used in humans in which there is a real advantage in choosing one option over the other such as in the Game of Dice (e.g. Labudda et al., 2010; Brandt et al., 2015) . By maintaining utility across both options, it is possible to detect subjective choice biases without the potential confounds caused by individual differences in the evaluation of differences in net gain.
Although the proportion of rats that responded to ropinirole by increasing preference for uncertainty on the rBT is considerably higher than the incidence of ICDs after DRT therapy, this may be because all the animals are repeatedly exposed to uncertain Fig. 2 . Chronic ropinirole increased choice of the uncertain lever on the betting task. Percent choice of the uncertain lever for all rats in the saline (A) and in the ropinirole-treated animals (B). (C-F) Percent choice of the uncertain lever in the sensitive and insensitive rats treated with saline or ropinirole. Rats receiving ropinirole increased their choice of the uncertain lever, and this did not depend on rats' baseline preference for the uncertain and safe lever. Choice behaviour in the non-responder (G) and responder rats (H). Eight rats of the 12 rats who received ropinirole responded to the drug by increasing their choice of the uncertain lever. Data shown are mean AE SEM.
outcomes, and this behavioural process can actually sensitize the dopamine system (Singer et al., 2012; Zack et al., 2014) . This shift towards selection of probabilistic over guaranteed outcomes also matches previous work in which repeated daily injections of pramipexole caused a similar effect on a probability discounting task, again irrespective of 6-OHDA depletion of the dorsolateral striatum . Hence, a similar bias towards uncertain outcomes is observed, regardless of pulsatile or slowrelease delivery, or which D 2/3 agonist is used. It has been found that food restriction may also increase sensitivity to the locomotor effects of stimulant drugs by increasing extracellular dopamine in response to dopamine agonist drugs and sensitizing D 2 receptors (Collins et al., 2008) . Although animals in this study were food restricted, it is unlikely that the effect on choice behaviour was due to the effect of food restriction as all rats were similarly food restricted at each experimental time point.
The mechanism by which DRTs enhance preference for uncertainty has yet to be fully determined. The effects of chronic ropinirole on the rBT are qualitatively similar to the increase in risky choice induced by amphetamine, although greater in magnitude (Cocker et al., 2012a) . The degree of wager sensitivity observed on task is also negatively correlated with D 2 receptor density in the dorsal, but not ventral, striatum (Cocker et al., 2012a) . Put another way, the greater the preference for the uncertain option, the greater the number of striatal D 2 receptors. Brief decreases in D 2 signalling within the striatum may be necessary for learning when an expected reward fails to arrive (Cohen & Frank, 2009 ). The constant stimulation of D 2 receptors by chronic ropinirole could therefore mask the Fig. 3 . Pictomicrograph representative of 6-hydroxydopamine lesion to the dorsolateral striatum. The extent of the lesions were determined and mapped with reference to a neuroanatomical rat brain atlas (Paxinos & Watson, 1998) . The right side of the micrograph was taken at 2.59 magnification (A). Chronic ropinirole increased choice of the uncertain lever. Percent choice of the uncertain lever in the saline (B) and in the ropinirole-treated animals (C). Similar to experiment 1, as a group, rats treated with ropinirole increased their choice of the uncertain lever when the bet size in play was larger. Choice behaviour in the non-responder (D) and responder rats (E). Sixteen rats of the 22 rats who received ropinirole responded to the drug. Data shown are mean AE SEM.
learning signal generated by non-reward, leading to an increase in preference for uncertain outcomes.
A growing body of literature indicates that dopaminergic receptor expression differs between drug addiction, GD and PD with ICD, despite some overlap in the symptoms and nature of the conditions (Potenza, 2014) . Individuals with long-term drug addiction show reduction in D 2 receptors in all subdivisions of the striatum, and low D 2 levels increase the likelihood of cocaine self-administration in rats (see Broft & Martinez, 2012 for review) . In contrast, no difference in D 2 receptors was observed between individuals with GD and healthy controls (Leeman & Potenza, 2013) . However, high levels of D 2 receptors have been observed in PD patients using positron emission topography (PET) during early stages of the disease, a time when the risk for developing ICDs in response to DRT is higher (Voon et al., 2007; Dagher & Robbins, 2009; Nikolaus et al., 2009 ), yet a recent report suggests that PD-ICD patients do not exhibit greater levels of D 2 or D 3 receptors as compared to PD patients without ICDs (Payer et al., 2015) . The difference observed in these populations may reflect differences in medications, which change neurotransmitter levels in brain. This may be particularly relevant to positron emission tomography (PET) studies, which measures displacement in neurotransmitter binding, and can therefore be influenced by basal dopaminergic tone. However, gambling severity and impulsivity have been associated with greater D 3 binding in the substantia nigra of individuals with GD (Boileau et al., 2013) . As a D 2/3 agonist, it is possible that D 3 receptor expression may also be involved in the increase in uncertain choice observed in our rats. Future rodent studies combining micro-PET and ex vivo receptor analysis would be useful to determine whether changes in striatal dopamine receptor density can explain the behavioural changes observed in response to dopamine agonist treatment, and also whether altered striatal dopamine density represents a pre-existing vulnerability marker for developing ICDs following DRTs.
With regard to the signalling mechanism by which constant stimulation of D 2/3 receptors may impact behaviour, there are two main intracellular pathways that are likely responsible. As an inhibitory G-protein-coupled receptor, D 2 receptor activation involves a reduction in cAMP production and inhibition of PKA, leading to decreased phosphorylation of DARPP at threonine 34. However, D 2 receptors also signal through a G-protein/cAMP-independent Akt/ GSK3b pathway mediated by b arrestin-2 (Beaulieu et al., 2005; Beaulieu & Gainetdinov, 2011; Li & Gao, 2011) . Inhibition of Akt1 phosphorylation by b arrestin-2 through protein phosphatase 2A (PP2A), increases GSK3b levels and has been observed following persistently elevated dopamine levels or dopamine agonist administration (Beaulieu et al., 2004) . Beta-arrestin-mediated signalling pathways have a slower onset, and a more prolonged duration than G-protein-mediated GPCR signalling. Furthermore, G-proteinmediated responses have a rapid onset and desensitization, whereas the desensitization mechanism for b arrestin-mediated cell signalling is unclear. It has therefore been hypothesized that the Akt/GSK3b pathway can dominate during prolonged, continuous stimulation of dopamine D 2 receptors, and may thus reflect long-lasting/tonic changes in dopamine concentrations or chronic agonist administration (Beaulieu & Gainetdinov, 2011) .
GSK3b has been involved in multiple neurological and psychiatric disorders such as drug addiction, schizophrenia and bipolar disorder, as well as in hyperdopamine-dependant behaviours (Beaulieu et al., 2004 (Beaulieu et al., , 2005 . It is therefore possible that this pathway may likewise contribute to the psychiatric side-effects of DRTs, potentially opening novel avenues to remediate these undesirable consequences of D 2 receptor administration without affecting their ability to treat symptoms of PD. Indeed, inhibition of GSK3b by lithium chloride or valproic acid has been suggested as a treatment for PD and case studies have shown that valproic acid may reduce symptoms of dopamine dysregulation syndrome in L-DOPA-medicated PD patients, and may help in controlling symptoms of ICDs in PD patients on DRTs (Hicks et al., 2011; Sriram et al., 2013; Wang et al., 2013; Epstein et al., 2014) . However, whether these drugs are appropriate for treating PD patients is unclear, with reports indicating an increase in dyskinesia symptoms when lithium is combined with L-DOPA (Dalen & Steg, 1973; Coffey et al., 1984) , worsening of PD symptoms with valproate in patients also taking L-DOPA (Hicks et al., 2011) and development of PD-like symptoms observed following treatment with either of these drugs (Masmoudi et al., 2006; Silver & Factor, 2013) . Given that lithium and valproic acid may be acting by multiple diverse mechanisms, it is currently unknown whether GSK3b inhibition is beneficial in reducing DRTinduced ICDs, or whether this action of the drug is responsible for the adverse effects encountered when interacting with other PD treatments or the pathology of PD itself.
Other drugs that work on the opioid, serotonin or glutamatergic systems have also been suggested as potential treatments for drugs and behavioural addiction disorders, some with promising results (see Leung & Cottler, 2009; Yau & Potenza, 2015 for review). It would be of interest to discover if these drugs can improve DRTinduced ICD in PD patients. Alternatively, a recent report suggested that modification in the OPRK1, HTR2A and DDC genes may be potential predictive genetic factors in the development of ICDs in PD patients on DRT (Kraemmer et al., 2016) . Predicting which PD patients are at risk for developing ICDs in response to DRT would improve DRT outcomes and increase patients' options when deciding between therapeutic strategies.
In sum, the data presented here suggest that enhanced preference for uncertainty following chronic administration of a D 2/3 agonist may serve as a behavioural endophenotype approximating DRTinduced ICDs. Furthermore, vulnerability to this effect appears independent of pre-morbid behavioural patterns. Determining the exact genetic mutation or mechanism that results in individual differences in the response to D 2 -receptor stimulation, thereby conferring resilience or vulnerability to DRT-induced ICDs, remains an important goal for future research that may inform therapeutic initiatives.
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